Rasagiline mesylate, >=98% (HPLC)

Not available outside of the UK & Ireland.

Application

Rasagiline mesylate has been used: to test its neuroprotective effects in retinitis pigmentosa (RP) by apoptosis regulator, Bax/Bcl-2 modulationas monoamine oxidase-B inhibitor in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced mouse modelas an anti-parkinsonian agent to test its rescue functionality in 6-hydroxydopamine-lesioned zebrafish larvae towards bradykinetic and dyskinetic-like behavior

Rasagiline mesylate may be used in MAO type B-mediated cell signaling studies.

Biochem/physiol Actions

Rasagiline mesylate is an effective therapeutic option in early stages of Parkinson′s disease. It improves the motor fluctuations in levodopa-treated patients and may be a useful adjunct to such patients. It has neuroprotective effects and increases the survival of dopaminergic neurons.

Rasagiline mesylate is an irreversible inhibitor of monoamine oxidase selective for MAO type B over type A by a factor of fourteen. It has anti-apoptotic and neuroprotectant activity and has been used as a treatment for Parkinson′s disease.

Features and Benefits

This compound is featured on the Dopamine and Norepinephrine Metabolism and Histamine Synthesis and Metabolism pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Packaging

10, 50 mg in glass bottle